Literature DB >> 22245895

Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up.

Shira Zelber-Sagi1, Roni Lotan, Amir Shlomai, Muriel Webb, Gil Harrari, Assaf Buch, Dorit Nitzan Kaluski, Zamir Halpern, Ran Oren.   

Abstract

BACKGROUND & AIMS: Data on the incidence and remission rates of non-alcoholic fatty liver disease (NAFLD) as well as predictive factors are scant. This study aims at evaluating NAFLD's epidemiology in prospective follow-up of individuals sampled from the general population.
METHODS: Evaluation of metabolic parameters and ultrasonographic evidence of NAFLD was performed in 213 subjects, with no known liver disease or history of alcohol abuse. The evaluation was performed at baseline and after a 7-year period by identical protocols.
RESULTS: Of the 147 patients who did not have NAFLD at baseline, 28 (19%) were found to have NAFLD at a 7-year follow-up. Baseline BMI, HOMA score, blood cholesterol, triglycerides, leptin levels, and weight gain (5.8±6.1 vs. 1.4±5.5kg, p<0.001) were significantly higher and adiponectin was lower among those who developed NAFLD at 7-year follow-up, compared with those who remained NAFLD-free. However, only weight gain and baseline HOMA were independent predictors for the development of NAFLD. Of the 66 patients who were found to have NAFLD at baseline, as many as 24 patients (36.4%) had no evidence of NAFLD at 7years. Weight loss of 2.7±5.0kg was significantly associated with NAFLD remission. Moreover, there was a 75% remission rate among NAFLD patients who lost 5% or more from their baseline weight.
CONCLUSIONS: Among the general population, weight gain, and baseline insulin resistance are predictors for NAFLD incidence. One third of NAFLD patients may have remission of disease within a 7-year follow-up, mostly depending on modest weight reduction. Copyright Â
© 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22245895     DOI: 10.1016/j.jhep.2011.12.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  70 in total

Review 1.  Nonalcoholic fatty liver disease in Asia: emerging perspectives.

Authors:  Wai-Kay Seto; Man-Fung Yuen
Journal:  J Gastroenterol       Date:  2016-09-16       Impact factor: 7.527

2.  Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial.

Authors:  Shira Zelber-Sagi; Assaf Buch; Hanny Yeshua; Nahum Vaisman; Muriel Webb; Gil Harari; Ofer Kis; Naomi Fliss-Isakov; Elena Izkhakov; Zamir Halpern; Erwin Santo; Ran Oren; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease.

Authors:  Karen E Stewart; James L Levenson
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

4.  Cost-utility analysis of nonalcoholic steatohepatitis screening.

Authors:  Eric Zhang; Claire Wartelle-Bladou; Luigi Lepanto; Jean Lachaine; Guy Cloutier; An Tang
Journal:  Eur Radiol       Date:  2015-05-21       Impact factor: 5.315

Review 5.  Epidemiology of fatty liver: an update.

Authors:  Giorgio Bedogni; Valerio Nobili; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 6.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 7.  Herbal medicines and nonalcoholic fatty liver disease.

Authors:  Hong Yao; Yu-Jie Qiao; Ya-Li Zhao; Xu-Feng Tao; Li-Na Xu; Lian-Hong Yin; Yan Qi; Jin-Yong Peng
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

8.  Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.

Authors:  Srinivasan Dasarathy; Jaividhya Dasarathy; Amer Khiyami; Lisa Yerian; Carol Hawkins; Ruth Sargent; Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2015-02       Impact factor: 3.062

9.  A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study.

Authors:  Michelle T Long; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Jiantao Ma; Rohit Loomba; Raymond T Chung; Emelia J Benjamin
Journal:  Liver Int       Date:  2018-03-12       Impact factor: 5.828

Review 10.  Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials.

Authors:  Shira Zelber-Sagi; Justyna Godos; Federico Salomone
Journal:  Therap Adv Gastroenterol       Date:  2016-03-17       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.